KR20220114572A - 1p36 결실 증후군의 치료적 치료를 위한 가복사돌 - Google Patents

1p36 결실 증후군의 치료적 치료를 위한 가복사돌 Download PDF

Info

Publication number
KR20220114572A
KR20220114572A KR1020227022608A KR20227022608A KR20220114572A KR 20220114572 A KR20220114572 A KR 20220114572A KR 1020227022608 A KR1020227022608 A KR 1020227022608A KR 20227022608 A KR20227022608 A KR 20227022608A KR 20220114572 A KR20220114572 A KR 20220114572A
Authority
KR
South Korea
Prior art keywords
gaboxadol
day
pharmaceutically acceptable
acceptable salt
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227022608A
Other languages
English (en)
Korean (ko)
Inventor
매튜 듀링
Original Assignee
오비드 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오비드 테라퓨틱스 인크. filed Critical 오비드 테라퓨틱스 인크.
Publication of KR20220114572A publication Critical patent/KR20220114572A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
KR1020227022608A 2019-12-18 2020-12-18 1p36 결실 증후군의 치료적 치료를 위한 가복사돌 Withdrawn KR20220114572A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949551P 2019-12-18 2019-12-18
US62/949,551 2019-12-18
PCT/US2020/065801 WO2021127308A1 (en) 2019-12-18 2020-12-18 GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME

Publications (1)

Publication Number Publication Date
KR20220114572A true KR20220114572A (ko) 2022-08-17

Family

ID=76439052

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227022608A Withdrawn KR20220114572A (ko) 2019-12-18 2020-12-18 1p36 결실 증후군의 치료적 치료를 위한 가복사돌

Country Status (10)

Country Link
US (1) US11364228B2 (cg-RX-API-DMAC7.html)
EP (1) EP4051272A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023507764A (cg-RX-API-DMAC7.html)
KR (1) KR20220114572A (cg-RX-API-DMAC7.html)
CN (1) CN114786669A (cg-RX-API-DMAC7.html)
AU (1) AU2020405060A1 (cg-RX-API-DMAC7.html)
CA (1) CA3164635A1 (cg-RX-API-DMAC7.html)
IL (1) IL293924A (cg-RX-API-DMAC7.html)
MX (1) MX2022007715A (cg-RX-API-DMAC7.html)
WO (1) WO2021127308A1 (cg-RX-API-DMAC7.html)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
US20050234093A1 (en) 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
EP1641456B1 (en) 2003-06-25 2010-03-03 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
US20070032553A1 (en) 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050137222A1 (en) 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
US20080262029A1 (en) 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090269795A1 (en) 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090048288A1 (en) 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
WO2010015037A1 (en) 2008-08-08 2010-02-11 Howard Florey Institute Therapeutic methods and compositions
CN102137667A (zh) 2008-09-01 2011-07-27 H.隆德贝克有限公司 包含加波沙朵和patl或oat抑制剂的药物组合物
US20150313913A1 (en) 2013-02-05 2015-11-05 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
AU2015243449A1 (en) * 2014-04-09 2016-09-29 Lineagen, Inc. Genetic markers associated with chromosomal deletion and duplication syndromes
EP3795156A1 (en) 2014-06-06 2021-03-24 Ovid Therapeutics, Inc. Pharmaceutical composition for treating angelman syndrome
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
CN108024997A (zh) 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions

Also Published As

Publication number Publication date
US20210186938A1 (en) 2021-06-24
JP2023507764A (ja) 2023-02-27
EP4051272A4 (en) 2023-01-04
IL293924A (en) 2022-08-01
CA3164635A1 (en) 2021-06-24
CN114786669A (zh) 2022-07-22
AU2020405060A1 (en) 2022-06-09
WO2021127308A1 (en) 2021-06-24
EP4051272A1 (en) 2022-09-07
US11364228B2 (en) 2022-06-21
MX2022007715A (es) 2022-07-19

Similar Documents

Publication Publication Date Title
EP2968121B1 (en) Sublingual and buccal film compositions
CA2845634A1 (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine
KR20120104543A (ko) 시술 환경에서 경도의 진정, 불안해소 및 진통을 위한 조성물 및 방법
CA3077514C (en) Delayed release deferiprone tablets and methods of using the same
ES2986170T3 (es) Sistema terapéutico transmucosal que contiene agomelatina
BRPI0711997A2 (pt) preparaÇço farmacÊutica, uso de uma forma de dosagem, uso de uma combinaÇço de agentes ativos, mÉtodo para o tratamento terapÊutico de um indivÍduo e mÉtodo para a produÇço de uma forma de dosagem no formato de uma folha
CN101622013A (zh) 包含丁丙诺啡和纳洛酮的改善的药用组合物
TW201717944A (zh) 用於重症治療時之鎮靜方法及非口服調配物
JP7705862B2 (ja) アゴメラチンを含有する経粘膜治療システム
ES2970294T3 (es) Tratamiento del prurito urémico
KR20250156085A (ko) 레미마졸람을 포함하는 구강 점막 전달 시스템
US20240252447A1 (en) Pharmaceutical formulations containing gaboxadol for therapeutic treatment
US11364228B2 (en) Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
CN101155578A (zh) 采用药物组合治疗的方法以及适合于该方法的药物组合
JP2022511673A (ja) 運動障害を処置するためのガボキサドール、ガナキソロンおよびアロプレグナノロンの使用
JP2007509031A (ja) ガランタミンの口腔用製剤およびその使用
KR20240023530A (ko) 아픽사반 필름 생성물 및 이의 용도
AU2005215782A1 (en) Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US20250073214A1 (en) Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US20110195996A1 (en) Transmucosal Treatment Methods in Patients With Mucositis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000